MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Buys 420,082 Shares of Pfizer Inc. (NYSE:PFE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 25.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,079,326 shares of the biopharmaceutical company’s stock after acquiring an additional 420,082 shares during the period. Pfizer accounts for approximately 2.3% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s portfolio, making the stock its 6th biggest position. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Pfizer were worth $59,864,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the 1st quarter worth $29,000. Briaud Financial Planning Inc purchased a new stake in Pfizer in the 3rd quarter valued at approximately $30,000. GoalVest Advisory LLC increased its position in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

Shares of Pfizer stock traded down $0.03 during trading hours on Friday, reaching $27.75. The stock had a trading volume of 40,466,657 shares, compared to its average volume of 47,662,984. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a market capitalization of $157.14 billion, a price-to-earnings ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61. The firm has a 50 day simple moving average of $27.45 and a two-hundred day simple moving average of $29.45.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.14 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Barclays decreased their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Truist Financial cut their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.